Targeting a specific enzyme to improve cancer treatment outcomes in breast cancer and melanoma
Official title: Targeting ATP-citrate lyase (ACLY) to overcome therapy resistance in breast cancer and melanoma
Funded at Pace University New York · NIH-10580197 · Data updated 2026-11-12
This study is looking at how a specific enzyme called ACLY affects breast cancer and melanoma, and it aims to see if blocking this enzyme can help make current treatments work better for patients who have developed resistance to them.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pace University New York NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | December 9, 2022 |
| Project end | November 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $400,241 |
| NIH project number | 1R15CA277653-01 |
| Project ID | NIH-10580197 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with breast cancer or melanoma who are experiencing treatment resistance.
✕Less likely to help
Patients with early-stage cancer who have not yet undergone treatment may not benefit from this research.
What this research studies
This research investigates the role of ATP-citrate lyase (ACLY) in breast cancer and melanoma, focusing on how cancer cells develop resistance to existing therapies. By inhibiting ACLY, which is linked to cancer cell metabolism and growth, the study aims to enhance the effectiveness of current treatments. The approach involves combining ACLY inhibitors with established therapies to potentially overcome resistance mechanisms that cancer cells use to evade treatment. Patients may be monitored for changes in tumor response and overall health as part of this innovative strategy.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with breast cancer and melanoma who have developed resistance to current therapies.
How similar studies have gone: Other research has shown promising results in targeting metabolic pathways in cancer, suggesting that this approach could be effective.
Where this research is happening
-
Pace University New York
New York, United States Active
Researchers
- Principal investigator: Krucher, Nancy a — Pace University New York
- Study coordinator: Krucher, Nancy a
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.